IN BRIEF: Keller CEO to undergo medical treatment, will stay in role

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Keller Group PLC - London-headquartered geotechnical engineering company - Chief Executive Officer Michael Speakman ‘will be undergoing necessary medical treatment’, but will continue in his role supported by Non-Executive Chair Carl-Peter Forster, the executive committee and Chief Financial Officer David Burke.

‘Michael will remain actively engaged in key strategic decisions and day-to-day leadership,’ Keller Group says. ‘The board and the entire company are fully supportive of Michael during this period.’

Current stock price: 1,558.00 pence

12-month change: up 13%

Copyright 2025 Alliance News Ltd. All Rights Reserved.